Genetic profiling may identify patients at higher risk of recurrence, such as individuals with mutations in KRAS, BAP1, or CDKN2A in intrahepatic CCA or mutations in P53, BRCA1-2, and PIK3CA in hilar CCA [75,76,77]. This evidence concerns the gene TP53 and cholangiocarcinoma.